What Is Ketamine Therapy

Ketamine therapy involves the clinical administration of sub-anesthetic doses of ketamine, a dissociative anesthetic, to treat conditions such as treatment-resistant depression, PTSD, anxiety, and chronic pain. It is delivered through intravenous infusion, intramuscular injection, sublingual lozenge, or intranasal spray (esketamine) under medical supervision. The therapy is distinguished from conventional antidepressant approaches by its rapid onset of action, often within hours, and its distinct mechanism involving glutamate signaling rather than monoamine neurotransmitters.

Depression, PTSD, and chronic pain are not merely quality-of-life concerns; they accelerate biological aging. Chronic depression is associated with increased systemic inflammation, elevated cortisol, shortened telomeres, and reduced BDNF, all of which contribute to faster cellular decline and increased risk of age-related disease. Chronic pain states similarly drive persistent sympathetic activation and neuroinflammation, creating a feedback loop that degrades resilience over time.

Ketamine therapy intersects with longevity through its capacity to rapidly interrupt these cycles. By restoring synaptic density in prefrontal and hippocampal circuits, it can help re-establish the neural architecture that supports stress regulation, executive function, and emotional processing. Because the brain's ability to adapt and repair (neuroplasticity) is a core determinant of cognitive healthspan, interventions that directly enhance plasticity carry significance beyond their immediate psychiatric applications.

Ketamine's primary pharmacological target is the NMDA (N-methyl-D-aspartate) receptor, an ionotropic glutamate receptor involved in synaptic transmission and plasticity. At sub-anesthetic doses, ketamine blocks NMDA receptors on GABAergic interneurons, which paradoxically increases glutamate release in the prefrontal cortex and hippocampus. This glutamate surge activates AMPA receptors, triggering intracellular signaling through the mTOR (mechanistic target of rapamycin) pathway and increasing production of BDNF.

The downstream effect of this BDNF surge is rapid synaptogenesis, the formation of new synaptic connections between neurons. Animal studies and human neuroimaging data indicate that ketamine can restore dendritic spine density in brain regions where chronic stress and depression have caused measurable synaptic atrophy. This structural repair helps explain why ketamine's antidepressant effects can emerge within hours rather than the weeks required by selective serotonin reuptake inhibitors, which operate through entirely different mechanisms.

Ketamine also modulates opioid receptors, sigma receptors, and monoamine transporters to varying degrees, contributing to its analgesic and dissociative properties. The dissociative state itself may have therapeutic relevance; some clinicians combine ketamine administration with psychotherapy sessions, hypothesizing that the altered state of consciousness facilitates processing of traumatic memories and rigid thought patterns. Esketamine, the S-enantiomer of ketamine approved by the FDA for treatment-resistant depression, has a higher affinity for NMDA receptors than racemic ketamine, though clinical data have not clearly established its superiority over the racemic form.

A ketamine therapy session typically begins with a pre-treatment assessment of vital signs, mood, and any contraindications. For intravenous infusions, the most common clinical route, a small IV catheter is placed and the infusion runs over approximately 40 minutes at a carefully calibrated sub-anesthetic dose. During the infusion, patients often experience dissociation, a sensation of floating or detachment, along with altered visual or auditory perception. These effects are dose-dependent and generally manageable in a controlled setting with dimmed lights, comfortable seating or reclining, and sometimes calming music or eyeshades.

A clinician or nurse monitors blood pressure, heart rate, and oxygen saturation throughout. After the infusion concludes, patients remain under observation for 30 to 60 minutes until the acute dissociative effects subside. Most people feel drowsy or mildly disoriented for a few hours afterward and should not drive or operate heavy equipment for the rest of the day. Some clinics integrate a brief psychotherapy session either during the infusion or in the hours following, when neuroplasticity is thought to be transiently heightened.

Intramuscular injections follow a similar timeline but with a slightly faster onset. Intranasal esketamine (Spravato) is self-administered under direct clinical observation, with a mandatory two-hour monitoring period. Sublingual lozenges, sometimes prescribed for at-home use between clinic visits, produce milder effects and are typically used as maintenance rather than as the primary treatment modality.

The standard induction protocol for IV ketamine involves six infusions delivered over two to three weeks, often scheduled on a Monday-Wednesday-Friday pattern. This loading phase is designed to build cumulative neuroplastic effects rather than relying on a single session. After the induction series, patients and clinicians assess response and determine a maintenance schedule, which commonly ranges from one infusion every two weeks to one per month, depending on symptom recurrence.

Esketamine nasal spray protocols, as outlined in the FDA label, involve twice-weekly sessions for the first month, weekly sessions for the second month, and then weekly or biweekly sessions thereafter. Some patients eventually extend intervals further or discontinue if remission holds. The total duration of treatment is highly individual; some patients use ketamine therapy for months, while others continue periodic maintenance for years. Long-term data beyond two to three years of continuous use are sparse, and clinicians generally aim for the lowest effective frequency.

IV ketamine infusions typically cost between $400 and $800 per session in the United States, with a six-session induction series therefore ranging from approximately $2,400 to $4,800. These costs are generally not covered by standard health insurance, though some clinics offer package pricing. Esketamine (Spravato), because it is FDA-approved, is more frequently covered by insurance, but out-of-pocket costs without coverage can exceed $600 per session. Sublingual ketamine prescriptions, when available through telemedicine or compounding pharmacies, tend to be less expensive per dose, often in the range of $100 to $300 per month, though they require an established clinical relationship and monitoring visits that add to the total cost. Prices vary substantially by geography, clinic setting, and whether psychotherapy integration is included.

The evidence base for ketamine therapy varies by indication. For treatment-resistant depression, multiple randomized controlled trials have demonstrated rapid antidepressant effects, typically within 24 hours of a single infusion. This evidence was sufficient for the FDA to approve esketamine (Spravato) in 2019 for treatment-resistant depression and, later, for major depressive disorder with suicidal ideation. However, most trials are short in duration, and long-term data on sustained efficacy and safety over years of maintenance treatment remain limited.

For PTSD, chronic pain, and anxiety disorders, the evidence is less mature. Smaller randomized trials and open-label studies suggest benefit, but the body of research has not reached the same level of rigor or consistency as for depression. The optimal dosing, route of administration, and frequency remain subjects of active investigation, with no clear consensus across the field. Concerns about long-term cognitive effects, bladder toxicity (documented primarily in recreational users at higher doses), and the potential for psychological dependence have not been fully resolved by existing clinical data. Studies combining ketamine with psychotherapy are in early stages, with preliminary results suggesting enhanced outcomes compared to ketamine alone, though this remains an area where controlled trials are needed.

Short-term side effects during and after infusion include dissociation, dizziness, nausea, transient blood pressure elevation, and altered perception; these typically resolve within two hours. Repeated use at high doses carries documented risk of bladder toxicity (interstitial cystitis), liver enzyme elevation, and cognitive effects, though clinical protocols use substantially lower doses than recreational contexts. Psychological dependence is a concern, particularly with at-home sublingual formulations that reduce clinical oversight. Individuals with a history of psychosis, uncontrolled hypertension, active substance use disorder, or certain cardiovascular conditions face elevated risk. A thorough medical and psychiatric evaluation by a qualified clinician before and throughout treatment is the standard of responsible practice.